SMURF2 in Anticancer Therapy: Dual Role in Carcinogenesis and Theranostics

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Cancer's cellular heterogeneity necessitates genetic and molecular profiling for targeted therapy.
• Drug resistance and lack of therapeutic targets, as seen in triple-negative breast cancer (TNBC), highlight the need for novel biomarkers.
• Ubiquitin E3 ligases, including SMURF2, are differentially expressed in cancers, presenting potential therapeutic targets.

Purpose of the Study:

• To review the multifaceted role of SMURF2 in carcinogenesis.
• To analyze the context-dependent functions of SMURF2 in cellular pathways.
• To discuss SMURF2's involvement in cancer therapy resistance and sensitivity.

Main Methods:

• Literature review of SMURF2's function in various cancers.
• Analysis of SMURF2's role in cellular signaling and ubiquitination pathways.
• Examination of existing literature on SMURF2 and cancer drug resistance.

Main Results:

• SMURF2 exhibits a dual role in cancer, acting as both an oncogene and a tumor suppressor depending on the context.
• Dysregulation of SMURF2 impacts multiple cancer-related pathways, influencing therapy resistance.
• Targeting SMURF2 requires a nuanced approach due to its diverse substrates and context-specific functions.

Conclusions:

• SMURF2 presents a complex target for cancer therapy, with potential for both inhibition and enhancement strategies.
• Further research into SMURF2's precise mechanisms is crucial for developing effective anticancer agents.
• Theranostic strategies incorporating SMURF2 biomarkers could improve personalized cancer treatment.